Overview

Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The principle aim of this study is to obtain safety, tolerability and pharmacokinetic data when LEO 39652 cream is administered cutaneously as single dose to subjects with atopic dermatitis and to healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
LEO Pharma